(Q37530452)

English

International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100).

scientific article published on 25 June 2009

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

20 August 2017

International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100). (English)

1 reference

Europe PubMed Central

20 August 2017

multiple myeloma

1 reference

based on heuristic

inferred from title

object named as

R Hajek

14

0 references

Giampaolo Merlini

object named as

G Merlini

11

0 references

Angela Dispenzieri

object named as

A Dispenzieri

9

0 references

Athanasios Dimopoulos

18

object named as

M A Dimopoulos

1 reference

Europe PubMed Central

20 August 2017

S. Vincent Rajkumar

38

object named as

S V Rajkumar

1 reference

Europe PubMed Central

20 August 2017

Edward A. Stadtmauer

2

object named as

E A Stadtmauer

1 reference

Europe PubMed Central

20 August 2017

22

object named as

M Gertz

1 reference

Europe PubMed Central

20 August 2017

20

object named as

B Barlogie

1 reference

Europe PubMed Central

20 August 2017

39

object named as

B G M Durie

1 reference

Europe PubMed Central

20 August 2017

author name string

S Giralt

1

1 reference

Europe PubMed Central

20 August 2017

J L Harousseau

3

1 reference

Europe PubMed Central

20 August 2017

A Palumbo

4

1 reference

Europe PubMed Central

20 August 2017

W Bensinger

5

1 reference

Europe PubMed Central

20 August 2017

R L Comenzo

6

1 reference

Europe PubMed Central

20 August 2017

S Kumar

7

1 reference

Europe PubMed Central

20 August 2017

N C Munshi

8

1 reference

Europe PubMed Central

20 August 2017

R Kyle

10

1 reference

Europe PubMed Central

20 August 2017

J San Miguel

12

1 reference

Europe PubMed Central

20 August 2017

H Ludwig

13

1 reference

Europe PubMed Central

20 August 2017

S Jagannath

15

1 reference

Europe PubMed Central

20 August 2017

J Blade

16

1 reference

Europe PubMed Central

20 August 2017

S Lonial

17

1 reference

Europe PubMed Central

20 August 2017

H Einsele

19

1 reference

Europe PubMed Central

20 August 2017

K C Anderson

21

1 reference

Europe PubMed Central

20 August 2017

M Attal

23

1 reference

Europe PubMed Central

20 August 2017

P Tosi

24

1 reference

Europe PubMed Central

20 August 2017

P Sonneveld

25

1 reference

Europe PubMed Central

20 August 2017

M Boccadoro

26

1 reference

Europe PubMed Central

20 August 2017

G Morgan

27

1 reference

Europe PubMed Central

20 August 2017

O Sezer

28

1 reference

Europe PubMed Central

20 August 2017

M V Mateos

29

1 reference

Europe PubMed Central

20 August 2017

M Cavo

30

1 reference

Europe PubMed Central

20 August 2017

D Joshua

31

1 reference

Europe PubMed Central

20 August 2017

I Turesson

32

1 reference

Europe PubMed Central

20 August 2017

W Chen

33

1 reference

Europe PubMed Central

20 August 2017

K Shimizu

34

1 reference

Europe PubMed Central

20 August 2017

R Powles

35

1 reference

Europe PubMed Central

20 August 2017

P G Richardson

36

1 reference

Europe PubMed Central

20 August 2017

R Niesvizky

37

1 reference

Europe PubMed Central

20 August 2017

IMWG

40

1 reference

Europe PubMed Central

20 August 2017

publication date

25 June 2009

1 reference

Europe PubMed Central

20 August 2017

1 reference

Europe PubMed Central

20 August 2017

23

1 reference

Europe PubMed Central

20 August 2017

10

1 reference

Europe PubMed Central

20 August 2017

1904-1912

1 reference

Europe PubMed Central

20 August 2017

https://scigraph.springernature.com/pub.10.1038/leu.2009.127

0 references

Association of CD34 cell dose with hematopoietic recovery, infections, and other outcomes after HLA-identical sibling bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.127

21 January 2018

Impact of CD34+ cell dose on the outcome of patients undergoing reduced-intensity-conditioning allogeneic peripheral blood stem cell transplantation.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.127

21 January 2018

CD34 cell dose in granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cell grafts affects engraftment kinetics and development of extensive chronic graft-versus-host disease after human leukocyte antigen-identical sibling tr

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.127

21 January 2018

Very large amounts of peripheral blood progenitor cells eliminate severe thrombocytopenia after high-dose melphalan in advanced breast cancer patients

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.127

21 January 2018

Predictive factors for hematopoietic engraftment after autologous peripheral blood stem cell transplantation for AL amyloidosis.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.127

21 January 2018

Secondary failure of platelet recovery after hematopoietic stem cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.127

21 January 2018

Comparison of peripheral blood progenitor cell mobilization in patients with multiple myeloma: high-dose cyclophosphamide plus GM-CSF vs G-CSF alone.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.127

21 January 2018

Mobilization of peripheral blood stem cells with chemotherapy and recombinant human granulocyte colony-stimulating factor (rhG-CSF): a randomized evaluation of different doses of rhG-CSF.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.127

21 January 2018

Randomized comparison of granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.127

21 January 2018

High-dose cyclophosphamide with or without etoposide for mobilization of peripheral blood progenitor cells in patients with multiple myeloma: efficacy and toxicity

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.127

21 January 2018

The VAD chemotherapy regimen plus a G-CSF dose of 10 μg/kg is as effective and less toxic than high-dose cyclophosphamide plus a G-CSF dose of 5 μg/kg for progenitor cell mobilization: results from a monocentric study of 82 patients

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.127

21 January 2018

The Arkansas approach to therapy of patients with multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.127

21 January 2018

DCEP chemotherapy followed by a single, fixed dose of pegylated filgrastim allows adequate stem cell mobilization in multiple myeloma patients.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.127

21 January 2018

Peripheral blood stem cell mobilization: new regimens, new cells, where do we stand

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.127

21 January 2018

Impact of lenalidomide therapy on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.127

21 January 2018

Effect of lenalidomide therapy on mobilization of peripheral blood stem cells in previously untreated multiple myeloma patients

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.127

21 January 2018

Compromised stem cell mobilization following induction therapy with lenalidomide in myeloma.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.127

21 January 2018

Stem cell mobilization with cyclophosphamide overcomes the suppressive effect of lenalidomide therapy on stem cell collection in multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.127

21 January 2018

Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.127

21 January 2018

Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: updated time-to-events results and prognostic factors for time to progression

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.127

21 January 2018

The use of AMD3100 plus G-CSF for autologous hematopoietic progenitor cell mobilization is superior to G-CSF alone

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.127

21 January 2018

High-dose therapy with single autologous transplantation versus chemotherapy for newly diagnosed multiple myeloma: A systematic review and meta-analysis of randomized controlled trials

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.127

21 January 2018

Single versus double autologous stem-cell transplantation for multiple myeloma.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.127

21 January 2018

Long-term outcome results of the first tandem autotransplant trial for multiple myeloma.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.127

21 January 2018

Single autologous stem-cell transplantation followed by maintenance therapy with thalidomide is superior to double autologous transplantation in multiple myeloma: results of a multicenter randomized clinical trial

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.127

21 January 2018

Salvage autologous or allogeneic transplantation for multiple myeloma refractory to or relapsing after a first-line autograft?

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.127

21 January 2018

Tandem versus single autologous hematopoietic cell transplantation for the treatment of multiple myeloma: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.127

21 January 2018

Current status of autologous hematopoietic stem cell transplantation in myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.127

21 January 2018

A comparison of allografting with autografting for newly diagnosed myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.127

21 January 2018

Impact of genetic abnormalities on survival after allogeneic hematopoietic stem cell transplantation in multiple myeloma.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.127

21 January 2018

International uniform response criteria for multiple myeloma.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.127

21 January 2018

Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: Bologna 96 clinical study

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.127

21 January 2018

Higher doses of CD34+ peripheral blood stem cells are associated with increased mortality from chronic graft-versus-host disease after allogeneic HLA-identical sibling transplantation

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.127

7 January 2021

based on heuristic

inferred from DOI database lookup

Preceding chemotherapy, tumour load and age influence engraftment in multiple myeloma patients mobilized with granulocyte colony-stimulating factor alone

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.127

7 January 2021

based on heuristic

inferred from DOI database lookup

Factors that influence collection and engraftment of autologous peripheral-blood stem cells

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.127

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparable engraftment kinetics following peripheral-blood stem-cell infusion mobilized with granulocyte colony-stimulating factor with or without cyclophosphamide in multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.127

7 January 2021

based on heuristic

inferred from DOI database lookup

Cyclophosphamide Mobilization Does Not Improve Outcome in Patients Receiving Stem Cell Transplantation for Multiple Myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.127

7 January 2021

based on heuristic

inferred from DOI database lookup

A single dose of 6 or 12 mg of pegfilgrastim for peripheral blood progenitor cell mobilization results in similar yields of CD34+ progenitors in patients with multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.127

7 January 2021

based on heuristic

inferred from DOI database lookup

Intermediate-dose CY and G-CSF more efficiently mobilize adequate numbers of PBSC for tandem autologous PBSC transplantation compared with low-dose CY in patients with multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.127

7 January 2021

based on heuristic

inferred from DOI database lookup

Predictive factors for a successful mobilization of peripheral blood CD34+ cells in multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.127

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical use of AMD3100 to mobilize CD34+ cells in patients affected by non-Hodgkin's lymphoma or multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.127

7 January 2021

based on heuristic

inferred from DOI database lookup

Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.127

7 January 2021

based on heuristic

inferred from DOI database lookup

A prospective PETHEMA study of tandem autologous transplantation versus autograft followed by reduced-intensity conditioning allogeneic transplantation in newly diagnosed multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.127

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1038/LEU.2009.127

1 reference

Europe PubMed Central

20 August 2017

Dimensions Publication ID

0 references

1 reference

Europe PubMed Central

20 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37530452&oldid=2076607380"